Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Capital Expenditures (2019 - 2025)

Summit Therapeutics (SMMT) has disclosed Capital Expenditures for 7 consecutive years, with $127000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Capital Expenditures rose 807.14% year-over-year to $127000.0, compared with a TTM value of $291000.0 through Dec 2025, up 109.35%, and an annual FY2025 reading of $291000.0, up 109.35% over the prior year.
  • Capital Expenditures was $127000.0 for Q4 2025 at Summit Therapeutics, up from $92000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $422000.0 in Q1 2025 and bottomed at -$350000.0 in Q2 2025.
  • Average Capital Expenditures over 5 years is $74400.0, with a median of $46000.0 recorded in 2021.
  • Peak annual rise in Capital Expenditures hit 10450.0% in 2025, while the deepest fall reached 8650.0% in 2025.
  • Year by year, Capital Expenditures stood at $120000.0 in 2021, then tumbled by 108.33% to -$10000.0 in 2022, then soared by 120.0% to $2000.0 in 2023, then skyrocketed by 600.0% to $14000.0 in 2024, then surged by 807.14% to $127000.0 in 2025.
  • Business Quant data shows Capital Expenditures for SMMT at $127000.0 in Q4 2025, $92000.0 in Q3 2025, and -$350000.0 in Q2 2025.